Plaintiff
5 cases as plaintiff.
Company overview. Amneal Pharmaceuticals LLC is the operating entity of Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), a publicly traded, fully integrated generics and specialty pharmaceutical company headquartered in Bridgewater, New Jersey. Founded in 2002 by brothers Chirag and Chintu Patel and publicly listed in 2018 after a reverse merger with Impax Laboratories, the company employs roughly 8,500–8,700 people and reported FY2024 net revenue of about $2.8 billion (≈$3.0 billion in FY2025). Public sources place its market cap in the $5.5–6.3 billion range.
Products / operations. Amneal develops, manufactures, and distributes a portfolio of roughly 280+ drug products across three segments: Affordable Medicines (retail generics, sterile injectables, and biosimilars — including oral solids, liquids, nasal sprays, transdermals, and ophthalmics), Specialty (branded CNS and endocrine products such as Rytary, Unithroid, and Ongentys), and AvKARE (pharmaceutical distribution to U.S. federal agencies including DoD and VA). It bills itself as the #4 U.S. generics portfolio by prescriptions and sales, with operations in the U.S., India, and Ireland.
Patent-litigation posture. Amneal is an operating company defending against a brand-owner suit — not an NPE. The tracked database shows one case, with Amneal as defendant and zero as plaintiff: a Hatch-Waxman/ANDA action filed in the District of Delaware (the typical venue for such cases), not a plaintiff-friendly forum like the Eastern District of Texas.
Notable case. In Neurelis, Inc. v. Amneal Pharmaceuticals LLC et al. (D. Del., filed March 11, 2026), Neurelis — maker of Valtoco® (diazepam) nasal spray — sued Amneal over ANDA No. 219109 seeking approval of generic 7.5 mg and 10 mg diazepam nasal sprays, asserting patents covering intranasal benzodiazepine compositions and treatment methods (including U.S. Patent Nos. 12,337,061 and 12,521,400). The case was consolidated before Judge Maryellen Noreika with related Neurelis ANDA litigation against Padagis and Lupin. It reflects Amneal's routine generics business of filing Paragraph IV challenges to branded CNS products. Amneal also acquired biopharmaceutical firm Kashiv BioSciences in August 2026.
Watchlist
Email-only, free, anonymous. We'll notify you when Amneal Pharmaceuticals, LLC files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Amneal filed an inter partes review against Jazz Pharmaceuticals on the '988 patent. The PTAB instituted the review and issued a final written decision in 2016 holding claims of the '988 patent unpatentable, as a companion to IPR2015-00551.
Par and Amneal petitioned for inter partes review of the '988 patent. The PTAB instituted the review and issued a final written decision on July 27, 2016 holding claims 1–15 of the '988 patent unpatentable as obvious over the Advisory Committee Art, with Korfhage as to claims 2 and 10.
Inter partes review petitioned by Amneal Pharmaceuticals, LLC et al. against Jazz Pharmaceuticals, Inc. The PTAB held all claims of US 7,765,107 unpatentable as obvious in a Final Written Decision on July 27, 2016; Jazz appealed and the Federal Circuit affirmed.
Cover Business Method review petition filed by Par, Roxane, and Amneal against Jazz Pharmaceuticals. The Board denied institution on January 13, 2015.
Amneal and Par filed a covered business method petition against Jazz Pharmaceuticals regarding the '988 patent in 2014. The PTAB did not institute the petition and denied it on procedural grounds.